MedPath

LTN Pharmaceuticals, Inc.

🇺🇸United States
Ownership
Private
Employees
-
Market Cap
-
Website
https://ltnpharma.com/

Clinical Trials

4

Active:0
Completed:2

Trial Phases

3 Phases

Phase 1:2
Phase 2:1
Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (50.0%)
Phase 2
1 (25.0%)
Phase 3
1 (25.0%)

Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Galeterone

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2016-04-06
Last Posted Date
2020-09-04
Lead Sponsor
LTN PHARMACEUTICALS, INC.
Target Recruit Count
6
Registration Number
NCT02729376
Locations
🇺🇸

Celerion, Lincoln, Nebraska, United States

A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC

Phase 3
Terminated
Conditions
Prostate Cancer
Interventions
First Posted Date
2015-05-08
Last Posted Date
2023-03-15
Lead Sponsor
LTN PHARMACEUTICALS, INC.
Target Recruit Count
953
Registration Number
NCT02438007
Locations
🇺🇸

Pinnacle Oncology Hematology, Scottsdale, Arizona, United States

🇺🇸

University Of Arizona Cancer Center, Tucson, Arizona, United States

🇺🇸

City of Hope, Duarte, California, United States

and more 112 locations

A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer

Phase 2
Terminated
Conditions
Prostate Cancer
Interventions
First Posted Date
2012-10-18
Last Posted Date
2023-03-15
Lead Sponsor
LTN PHARMACEUTICALS, INC.
Target Recruit Count
126
Registration Number
NCT01709734
Locations
🇺🇸

UCLA David Geffen School of Medicine, Los Angeles, California, United States

🇺🇸

San Bernardino Urological Associates, San Bernardino, California, United States

🇺🇸

Raton Regional Hospital, Lynn Cancer Institute, Boca Raton, Florida, United States

and more 20 locations

ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer

Phase 1
Completed
Conditions
Prostate Cancer
Interventions
First Posted Date
2009-08-17
Last Posted Date
2020-09-04
Lead Sponsor
LTN PHARMACEUTICALS, INC.
Target Recruit Count
49
Registration Number
NCT00959959
Locations
🇺🇸

UCLA, Los Angeles, California, United States

🇺🇸

San Bernardino Urological Associates, San Bernardino, California, United States

🇺🇸

Johns Hopkins Hospital, Baltimore, Maryland, United States

and more 5 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.